key: cord-0835058-4ined9rx
authors: Edmonston, Daniel L.; South, Andrew M.; Sparks, Matthew A.; Cohen, Jordana B.
title: COVID-19 and Hypertension: The Role of ACE2 and the Renin-Angiotensin System
date: 2020-07-04
journal: Adv Chronic Kidney Dis
DOI: 10.1053/j.ackd.2020.07.002
sha: 3103c81b61e85d49a67844da9d3541cda489fe1b
doc_id: 835058
cord_uid: 4ined9rx

ABSTRACT Hypertension emerged from early reports as a potential risk factor for worse outcomes for persons with coronavirus disease 2019 (COVID-19). Among the putative links between hypertension and COVID-19 is a key counter-regulatory component of the renin-angiotensin system (RAS): angiotensin-converting enzyme 2 (ACE2). ACE2 facilitates entry of SARS-CoV-2, the virus responsible for COVID-19, into host cells. Since RAS inhibitors have been suggested to increase ACE2 expression, healthcare providers and patients have grappled with the decision of whether to discontinue these medications during the COVID-19 pandemic. However, experimental models of analogous viral pneumonias suggest RAS inhibitors may exert protective effects against acute lung injury. We review how RAS and ACE2 biology may affect outcomes in COVID-19 through pulmonary and other systemic effects. In addition, we briefly detail the data for and against continuation of RAS inhibitors in persons with COVID-19 and summarize the current consensus recommendations from select specialty organizations.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in a devastating, multisystem disease which has affected millions of people worldwide. 1 This pandemic has sparked efforts to identify modifiable risk factors and investigate putative treatments. With the first wave of observational data, hypertension quickly emerged as a key comorbidity potentially associated with increased COVID-19 mortality. 1, 2 Identification of angiotensin-converting enzyme 2 (ACE2) as the primary SARS-CoV-2 binding site led to further concern that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) may increase SARS-CoV-2 infection and COVID-19 mortality risk. 3, 4 Select experimental studies have shown that ACE inhibitors and ARBs increase ACE2 expression in certain tissues. [5] [6] [7] However, data continue to emerge which either temper or refute these early concerns. 8, 9 In addition, these concerns contrast with prior experimental data, which suggest a protective role for these renin-angiotensin system (RAS) inhibitors against acute lung injury and inflammation in select viral pneumonias including SARS-CoV, the virus responsible for the SARS outbreak of 2003. Informed decisions to continue or discontinue ACE inhibitor or ARB therapy during COVID-19 hinge on ongoing research to understand the roles of ACE2 and the RAS in pulmonary biology and well-designed clinical trials targeting this patient population.

We review RAS biology and how this classic mediator of hypertension may also both hold the key to SARS-CoV-2 entry into pneumocytes and potentially modulate subsequent lung injury.

We also briefly review the competing data regarding the effect of RAS inhibition in COVID-19;

identify key unmet needs and the studies designed to address them; and summarize consensus recommendations regarding the use of RAS inhibition in COVID-19.

The RAS is a crucial regulator of numerous physiologic functions, including fluid and electrolyte balance, perfusion, and inflammatory response. The two predominant RAS axes, the ACE/angiotensin (Ang) II/type 1 Ang II receptor (AT 1 R) pathway and the counter-regulatory ACE2/Ang-(1-7)/Mas receptor (MasR) pathway, are co-expressed in most tissues. 10 ACE exists in membrane-bound and soluble forms and converts Ang I into Ang II that acts via the AT 1 R and AT 2 R, while ACE2 is predominately membrane-bound and converts Ang II into Ang- (1) (2) (3) (4) (5) (6) (7) which acts via the MasR. 11 Homeostasis between these pathways is critical for normal physiology, but in pathologic conditions, ACE/Ang II upregulation and/or ACE2/Ang-(1-7) downregulation propagates disease. 11, 12 The RAS has several effects on the cardiovascular system as well as target organs including the kidney and brain. Experimental models of acquired or genetic ACE2 deficiency associate with several deleterious structural and functional abnormalities attributed to unopposed Ang II as well as reduced Ang-(1-7), including decreased cardiac contractility, cardiac hypoperfusion, myocardial dysfunction, impaired kidney function, and albuminuria. [13] [14] [15] In the vasculature, Ang II acts on the AT 1 R, resulting in diminished nitric oxide and vasoconstriction. 16 In the kidneys, Ang II promotes sodium and fluid retention, which in combination with vasoconstriction raises blood pressure. On the other hand, Ang-(1-7) activation of the MasR results in part in the release of prostaglandin E 2 , bradykinin, and nitric oxide to decrease blood pressure via natriuresis, diuresis, and vasodilation. 11, 16 In the brain, the ACE2/Ang-(1-7) pathway reduces sympathetic activity and increases nitric oxide synthase and nitric oxide levels, further promoting vasodilation and blood pressure decline. 17, 18 In addition to its effects on the vasculature, Ang-(1-7) counteracts the pro-inflammatory and profibrotic effects of Ang II in the heart and kidneys. 19, 20 In animal models, unopposed Ang II in the setting of diminished ACE2 upregulated inflammatory cytokines interferon-γ, interleukin-6, and monocyte chemoattractant protein-1, and increased phosphorylation of extracellular signal-regulated protein kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK)1/2 signaling pathways. 21 Furthermore, AT 1 R activation by Ang II has pro-thrombotic effects, including enhanced platelet activation and impaired fibrinolysis, resulting in hypercoagulability. 22, 23 Ang II also stimulates plasminogen activator inhibitor-1, further promoting thrombus production. 24 The pro-thrombotic effects of Ang II are downregulated by ACE2-mediated conversion into Ang-(1-7) and subsequent Ang-(1-7) signaling via MasR. Dysregulation of this pathway may contribute to the hypercoagulability and endothelial dysfunction observed in COVID-19. 25, 26 

There has been increasing interest in the RAS, and ACE2/Ang-(1-7) in particular, during the COVID-19 pandemic given that the SARS-CoV-2 Spike protein binds to ACE2 to infect epithelial cells in the lung, most notably type II alveolar epithelial cells, which was the same mechanism observed with SARS-CoV. 27, 28 In the lungs, the RAS regulates pulmonary vascular tone, alveolo-capillary integrity, and inflammatory response. Alveolar epithelial cells, endothelial cells, smooth muscle cells, fibroblasts, and resident immune cells (i.e. alveolar macrophages) express both RAS pathways, though ACE/Ang II expression is generally much greater than ACE2/Ang-(1-7). 10,29-32 Lung injury upregulates and stimulates de novo ACE/Ang II expression and, notably, ACE2/Ang-(1-7)

suppression, which in turn propagates injury. 29, 30, [33] [34] [35] As with SARS-CoV, evidence suggests that SARS-CoV-2 downregulates ACE2 via endocytosis and shedding and thus could potentially shift the RAS towards ACE/Ang II. [36] [37] [38] [39] Acid aspiration-induced acute lung injury resulted in ACE-dependent increased Ang II concentrations in lung and plasma associated with reduced ACE2 expression. 34 In a rat acute respiratory distress syndrome (ARDS) model, a combination of lipopolysaccharide and mechanical ventilation decreased the ACE2/ACE activity and Ang-(1-7)/Ang II concentration ratios in bronchoalveolar lavage fluid. 29 Patients with ARDS had elevated plasma Ang II levels; 40 in addition, prior ACE inhibitor and ARB use, as well as ACE genotype, were associated with improved mortality in patients with ARDS. 41, 42 Ang II binds to AT 1 R to increase pulmonary vascular permeability, induce alveolar epithelial cell apoptosis and fibroblast differentiation, and promote immune cell migration, activation, differentiation, and cytokine release. 30, 34, [43] [44] [45] Indeed, cytokine release by activated type II alveolar epithelial cells and alveolar macrophages is mediated in part through ERK1/2 and p38 mitogen-activated protein kinase signaling cascades, which are regulated by AT 1 R and MasR. [45] [46] [47] The ACE2/Ang-(1-7) pathway mitigates acute lung injury/ARDS. The binding of the SARS-CoV Spike protein to ACE2 downregulated ACE2 expression, increased Ang II lung concentration, and enhanced AT 1 R-mediated acute lung injury, including increased lung elastance and pulmonary edema. 36 Further, ACE2 deficiency worsened lung elastance, pulmonary vascular permeability and pulmonary edema, inflammatory cell infiltration, and hyaline membrane formation and decreased oxygenation in several acute lung injury models; catalytically active recombinant human ACE2 improved these lung measures and reduced lung Ang II concentration. 34 In a phase-II clinical trial, recombinant human ACE2 caused a sustained decrease in plasma Ang II and a sustained increase in Ang-(1-7). 40 The beneficial effects of the ACE2/Ang-(1-7) pathway in acute lung injury extend beyond Ang II metabolism; Ang-(1-7) binding to MasR, and to a lesser extent Ang II binding to AT 2 R, also exerts a protective effect. 48 In several rodent models of acute lung injury, Ang-(1-7) infusion (peptide and cyclized) reduced pulmonary vascular resistance and edema, increased PaO 2 , blocked increased tumor necrosis factor α, increased bronchoalveolar lavage fluid ACE2/ACE activity and Ang-(1-7)/Ang II concentration ratios, and protected against alveolo-capillary barrier failure and neutrophil invasion. 29, 49 Intriguingly, Ang-(1-7) restored systemic blood pressure and reduced right ventricle pressure load and, in part, mediated beneficial ARB effects. 49 The RAS plays a significant role in acute and chronic lung injury, including SARS, and given ACE2's role as the SARS-CoV-2 binding site, the RAS likely plays a role in COVID-19 pathophysiology, though confirmatory clinical and experimental data are needed.

SARS-CoV-2 cellular entry via ACE2 is dependent upon priming of the SARS-CoV-2 Spike protein by type II transmembrane serine proteases. 3, 39 In addition, SARS-CoV-2 binds to ACE2 with a higher affinity than SARS-CoV. 50 Therefore, any process which increases ACE2 expression theoretically could increase the likelihood of viral binding, cellular infection, and thus increase the risk of worse outcomes in patients with COVID-19.

RAS inhibitors may increase cell surface ACE2 levels and expression. 5-7 ACE2 interacts with the AT 1 R on the cellular surface; however, Ang II binding to AT 1 R interrupts this AT 1 R-ACE2 interaction and promotes increased ACE2 internalization. 51 Among other complications of this multi-organ disease, COVID-19 may increase the risk for acute kidney injury (AKI); in studies of critically ill persons with COVID-19, the rate of AKI ranges from 19-39%. [54] [55] [56] However, AKI estimates for all hospitalized patients vary substantially and the incidence of AKI in outpatients with COVID-19 remains unknown. 1,2,56-58 Through impairment of the autoregulatory response to changes in kidney perfusion, 59,60 ACE inhibitors or ARBs could theoretically increase the risk of AKI in highly susceptible individuals. However, aside from the demonstrated risks of dual therapy, 61 neither ACE inhibitors nor ARBs clearly increase AKI risk in randomized studies of other at-risk populations. 62 Moreover, no study has directly demonstrated an association between RAS inhibition and the risk of AKI in patients with COVID-19. 58

Despite the theoretical increase in ACE2 binding sites, RAS blockade could improve clinical outcomes in persons infected with SARS-CoV-2. This rationale is supported by preclinical studies in which losartan, an ARB, attenuated lung injury in a non-viral mouse model of SARS-CoV Spike protein-enhanced acid-induced lung injury. 36 In this study, either infection with SARS-CoV or the use of Spike protein combined with an acid-inhalation model substantially reduced ACE2 levels and increased Ang II levels in the lung. Thus, the overarching hypothesis is that viral infection diminishes ACE2 protein and activity, leading to Ang II accumulation and reduced Ang-(1-7).

The aforementioned upregulation of ACE/Ang II and concomitant suppression of ACE2/Ang-(1-7) likely propagates lung injury during SARS-CoV-2 infection. 29, 30, [33] [34] [35] This increased Ang II/Ang-(1-7) ratio leads to vasoconstriction of the pulmonary vasculature, further reducing pulmonary blood flow to the already-damaged lung parenchyma in the face of hypoxemia from the viral pneumonia. The predominance of Ang II intensives the immune response which may further contribute to lung injury. 63 However, whether AT 1 R universally stimulates inflammation and fibrosis remains unclear: specific deletion of AT 1 Rs on both macrophages and T cells in mice suggests that activation of AT 1 Rs on these immune cell lineages limits rather than propagates inflammation and organ injury in kidney models. 64, 65 How AT 1 R signaling of macrophages and T cells contributes to lung injury during SARS-CoV-2 infection remains unknown.

While the benefits of RAS inhibition in COVID-19 remain unclear, we may be able to extrapolate from the use of RAS inhibition in other types of viral infections. For example, in a mouse model of H7N9 influenza, viral infection also decreased ACE2 levels (with resultant increased Ang II). 66 ACE2 knockout mice had worse outcomes after viral infection; in contrast, losartan mitigated lung injury in wild-type mice with influenza infection similar to the effect seen in the SARS-CoV model. 66 Moreover, respiratory syncytial virus models demonstrate similar improvements with RAS inhibition. 67 These data in other analogous viral infections provide a favorable precedent for the use of RAS inhibition in COVID-19.

Several observational studies have evaluated the association of ACE inhibitor and ARB therapy with the development and severity of COVID-19. 8, 9, 68, 69 These studies have several limitations, including confounding by indication, collider bias (conditioning on specific factors like hospitalization or for-symptom COVID-19 testing, which may distort or induce spurious associations between ACE inhibitor or ARB use and COVID-19), time-dependent bias, or lack of accounting for multiple hypothesis testing. Accordingly, the studies show conflicting results regarding the association of ACE inhibitor and ARB therapy with COVID-19. For example, Zhang et al. found that ACE inhibitor or ARB therapy was associated with lower risk of mortality among individuals hospitalized with COVID-19 in Hubei Province, China; 68 in contrast, Rentsch et al. found that ACE inhibitors and ARBs were associated with a higher risk of requiring intensive care among US veterans hospitalized with COVID-19. 69 Further research is needed to better understand the magnitude and direction of these associations.

The dizzying pace of research in the wake of the COVID-19 pandemic has yielded incomplete and conflicting data regarding the safety of RAS inhibitors for patients with COVID-19. For patients with certain comorbidities such as heart failure and chronic kidney disease, decades of research clearly demonstrate improved survival and disease trajectory with RAS inhibitors. 70, 71 Given the stakes of the decision to continue or hold these medications, patients and providers need clear guidelines to help navigate this difficult situation. While our understanding of COVID-19 continues to evolve, Table 1 summarizes the current consensus guidelines from select organizations regarding the use of RAS inhibitor therapy in persons affected by COVID-19. [72] [73] [74] [75] [76] [77] The measured and consistent responses from these organizations to continue RAS inhibitor therapy through SARS-CoV-2 infection unless otherwise directed by a healthcare provider reflect the lack of high-quality data to overturn the existing indications for these medications.

Several confounding factors -both measurable and unmeasurable -underlie the clinical decision to continue, discontinue, or start RAS inhibitor therapy in the setting of COVID-19; these confounding factors limit the ability of observational studies to definitively answer this question. infection nor do they affect the outcomes of those infected.

• Strongly recommend that the routine use of ACE inhibitors or ARBs 

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data

COVID-19, ACE2, and the cardiovascular consequences

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats

Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease

Classical Renin-Angiotensin system in kidney physiology

Central ANG-(1-7) infusion improves blood pressure regulation in antenatal betamethasoneexposed sheep and reveals sex-dependent effects on oxidative stress

Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure

Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB

Angiotensin-(1-7) and the G protein-coupled receptor MAS are key players in renal inflammation

Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction

The acute prothrombotic effect of aldosterone in rats is partially mediated via angiotensin II receptor type 1

Prothrombotic effects of angiotensin

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the reninangiotensin system and thrombosis

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme

Angiotensin II stimulates proliferation of human pulmonary artery smooth muscle cells via the AT1 receptor

Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis

Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study

Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome

Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II

AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes

Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages

Angiotensin II upregulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway

Counteraction between angiotensin II and angiotensin-(1-7) via activating angiotensin type I and Mas receptor on rat renal mesangial cells

Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury

Angiotensin-(1-7) protects from experimental acute lung injury

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism

Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Kidney disease is associated with in-hospital death of patients with COVID-19

Renal responses to antagonism of the renin-angiotensin system

Angiotensin converting enzyme inhibition and autoregulation of glomerular filtration

Combined angiotensin inhibition for the treatment of diabetic nephropathy

What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis

Essential roles for angiotensin receptor AT1a in bleomycininduced apoptosis and lung fibrosis in mice

Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis

Stimulating Type 1 Angiotensin Receptors on T Lymphocytes Attenuates Renal Fibrosis

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. medRxiv

ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the

Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Diagnosis and Management of Type 2 Diabetic Kidney Disease

COVID-19: An ACP Physician's Guide. American College of Physicians. Treatment: Pharmacotherapy Web site

HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19

Clinical Affairs & Pactice Management Committee: Position Statement on Covid-19 and ACE Inhibitor and Angiotensin Receptor Blocker Use in Children with Hypertension and Kidney Disease. COVID-19 Information Web site

Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers

the-International-Society-of-Hypertension-on-COVID-19/. Accessed May 1, 2020. 77. Considerations for Certain Concomitant Medications in Patients with COVID-19. COVID-19 Treatment Guidelines Web site

COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective

Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19)

Abbreviations: ACE, angiotensin-converting enzyme

Ang, angiotensin; ARB, angiotensin receptor blocker; CKD, chronic kidney disease

Mas receptor; RAS, renin-angiotensin system

The authors would like to acknowledge the extensive and expanding resources related to this topic provided by the editors of nephjc.com. We also thank The COVID-19 and ACE2 in 

JBC is supported by K23-HL133843 from the National Heart, Lung, and Blood Institute; AMS is supported by R01-HL146818 and L40-HL148910 from the National Heart, Lung, and Blood Institute. The funding sources had no involvement in the preparation of this article.